- NH Investment & Securities wereed as the lead underwriter and Korea Investment & Securities as the co-underwriter for SK bioscience’s IPO.
- SK bioscience plans to be listed for the next year to expand business and accelerate growth by securing new investment

SK bioscience announced that the company hased the NH Investment & Securities as a lead underwriter and Korea Investment & Securities as its co-underwriter to manage an initial public offering (IPO) for 2021.

SK bioscience plans to expand its business and accelerate further growth by securing new investment.

SK bioscience has developed SKYCellflu® Quadrivalent, the world´s first cell culture-based quadrivalent influenza vaccine, SKYZoster®, the world´s second shingles vaccine, and SKYVaricella®, the second varicella vaccine developed in Korea. New products currently being developed include a COVID-19 vaccine and a next-generation pneumococcal vaccine.

SK bioscience has been actively advancing to overseas markets and expanding its business portfolio. The company recently signed a CMO contract with AstraZeneca, a global pharmaceutical company, to supply COVID 19 vaccines in Korea and abroad.

A company official said, "The IPO will be conducted under proper evaluation.”